Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Non-Partisan Lawmaker Group on Healthcare Boots Up, Plans Fortnightly Hearings
A non-partisan group of lawmakers on the healthcare industry was launched on March 1 with 18 legislators from the ruling Liberal Democratic Party (LDP) and an opposition party, Nippon Ishin no Kai. The group, called “iryo sangyo giin renmei,” co-chaired…
To read the full story
Related Article
- Lawmakers Hear from EFPIA, Say They Didn’t Know Japan Drug Market Would Shrink
May 19, 2017
- Market Price Survey for Off-Year Revision Should “Cover All Products”: JPWA
May 15, 2017
- Lawmakers Whispering Thresholds for Off-Year-Revision Products; Top 30% in Discrepancy Rates Floated
April 21, 2017
- PhRMA Submits Paper to Lawmaker Group, Demands Price Maintenance for On-Patent Drugs
April 21, 2017
- Diet members Aim to Create Non-Partisan Forum for Healthcare Industry
December 14, 2016
REGULATORY
- Japan Begins Review of Domestic CGT Seeds with Limited Market Potential
June 30, 2026
- Govt Panel Urges 2027 Bill to Expand Secondary Use of Health Data
June 30, 2026
- Japan Panel OKs Carvykti’s Earlier Use in Multiple Myeloma
June 30, 2026
- Govt to Explore Greater Rewards for Innovative Drugs in Honebuto
June 29, 2026
- MHLW Starts Technical Review of OTC-Like Drug Charge Exemptions
June 29, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…